Normal cellular lifespan is contingent upon preserving outer mitochondrial membrane (OMM) integrity, as permeabilization promotes apoptosis. BCL-2 family proteins control mitochondrial outer membrane permeabilization (MOMP) by regulating the activation of the pro-apoptotic BCL-2 effector molecules, BAX and BAK. Sustainable cellular stress induces proteins (e.g., BID, BIM, and cytosolic p53) capable of directly activating BAX and/or BAK, but these direct activators are sequestered by the anti-apoptotic BCL-2 proteins (e.g., BCL-2, BCL-xL, and MCL-1). In the event of accumulated or marked cellular stress, a coordinated effort between previously sequestered and nascent BH3-only proteins inhibits the anti-apoptotic BCL-2 repertoire to promote direct activator proteinmediated MOMP. We examined the effect of ABT-737, a BCL-2 antagonist, and PUMA, a BH3-only protein that inhibits the entire anti-apoptotic BCL-2 repertoire, with cells and mitochondria that sequestered direct activator proteins. ABT-737 and PUMA cooperated with sequestered direct activator proteins to promote MOMP and apoptosis, which in the absence of ABT-737 or PUMA did not influence OMM integrity or cellular survival. Our data show that the induction of apoptosis by inhibition of the anti-apoptotic BCL-2 repertoire requires ''covert'' levels of direct activators of BAX and BAK at the OMM.
T
he mitochondrial pathway of apoptosis requires the release of cytochrome c from the mitochondrial intermembrane space to the cytosol (1, 2) . Once released, cytochrome c cooperates with the adaptor protein, APAF-1, to promote the activation of caspases, which are required for the rapid recognition and clearance of the stressed cell. The major function of the BCL-2 family of proteins is to control the integrity of the outer mitochondrial membrane (OMM) (3, 4) . The pro-apoptotic multidomain BCL-2 effector proteins, BAX and BAK, oligomerize into proteolipid pores and permeabilize the OMM, allowing the efflux of cytochrome c and other intermembrane space proteins to the cytosol during apoptosis (4, 5) .
The activation of BAX and BAK, to insert, oligomerize and permeabilize the OMM is a function of the BH3-only proteins, which are further classified into direct activators and derepressors/ sensitizers (6, 7) . Direct activator BH3-only proteins, such as BID and BIM, activate BAX and BAK at the OMM leading to cytochrome c release (6) (7) (8) . BH3 domain peptides derived from BID and BIM behave similarly to the intact proteins as they also induce BAX and BAK oligomerization and pore-forming activity in the absence of additional mitochondrial proteins (6, 7) . A few non-BCL-2 family proteins are also described and can have direct activator function, perhaps most clearly demonstrated in the case of cytosolic p53 (9, 10) . Conversely, the derepressor/sensitizer BH3-only proteins (e.g., BAD, BIK, BMF, HRK, and Noxa) fail to directly induce BAX and BAK activation, but efficiently release sequestered direct activator proteins from anti-apoptotic BCL-2 members, such as BCL-2, BCL-xL and MCL-1, to promote mitochondrial outer membrane permeabilization (MOMP) (6, 7, 11) . However, most of the data concerning derepressor/sensitizer BH3-only protein function were obtained solely from the use of synthesized BH3 domain peptides; there is little information about full-length derepressor/ sensitizer BH3-only proteins. A small molecule BH3 domain peptide mimetic, ABT-737, acts similarly to derepressor/sensitizer BH3-only peptides (e.g., BAD) by rapidly inducing direct activator dependent MOMP in some tumor model systems (12, 13) . The potency and selectivity of ABT-737 supports the notion that tumor cells become addicted to anti-apoptotic proteins which sequester direct activators induced during oncogenesis and provides in vivo evidence that a direct activator:anti-apoptotic:derepressor (e.g., BIM:BCL-2:ABT-737) network regulates MOMP (14) . As an example, cells derived from chronic lymphocytic leukemia (CLL) constitutively express BIM that must be tonically inhibited by BCL-2 or MCL-1 to escape MOMP and ensure tumor maintenance; the inhibition by BCL-2 can be overcome by ABT-737 treatment leading to BIM release and activity (13) . The BH3-only protein PUMA (there are two major isoforms, ␣ and ␤, which share identical BH3 regions and similar kinetics for the induction of apoptosis) promotes MOMP in numerous cellular stress scenarios, such as cytokine deprivation and DNA damage (15) (16) (17) . Original observations on PUMA indicate that it is a potent inducer of cell death, perhaps solely due to the inhibition of the anti-apoptotic BCL-2 repertoire or through cooperation with direct activator proteins (11, (15) (16) (17) (18) . Here, we describe several cellular and in vitro derepressor/sensitizer model systems to investigate the synergy between ABT-737 or PUMA with direct activator proteins. In addition, we provide evidence that PUMA can reveal covert direct activator BH3-only protein function on mitochondria derived from healthy tissue. dependent caspase inhibition (20) . Cells were treated for 6 h, then untreated for 42 h and this cycle was repeated through several rounds. After this TNF treatment, cells displayed the accumulation of C8-BID (a complex containing two fragments: amino terminal p7 and a carboxyl terminal p15); however these doses of TNF did not induce cell death (Fig. 1B) . The TNF-treated clones were then analyzed for apoptosis 4 h after the addition of 1 M ABT-737. ABT-737 induced marked apoptosis in the TNF-treated clones, with clone 6 showing the greatest response (Fig. 1C) . Since ABT-737 inhibits only a subset of the anti-apoptotic BCL-2 repertoire (BCL-2, BCL-xL, and BCL-w) (12) , the complete inhibition of the anti-apoptotic BCL-2 repertoire [BCL-2-like and MCL-1-like members which are both present in these cells, supporting information (SI) Fig. S1 A] was examined with highly active full-length, recombinant PUMA␤ (the activity was determined as binding to BCL-xL⌬C by NMR spectroscopy, Fig. S2 A-D) . The clones were microinjected with PUMA␤ (and Texas Red dextran to mark the microinjected cells), cultured for 3 h, and analyzed for MOMP by imaging the punctate (mitochondrial) to a diffuse cytosolic (released from mitochondria) transition of cytochrome c-GFP by confocal microscopy ( Fig. 1 D-E) . Purified heavy membrane fractions (enriched for mitochondria) from these cells released cytochrome-GFP and endogenous cytochrome c with identical direct activator concentrations and kinetics (Fig. S1B) ; therefore, cytochrome c-GFP is an accurate measure of MOMP. Cells expressing C8-BID released cytochrome c-GFP rapidly, with clones 5 and 6 displaying almost 100% diffuse cytochrome c staining after only 60 min. The microinjected cells were also treated with 20 M quinolylvalyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone (Q-VD-OPh), a pan-caspase inhibitor, to block caspase-dependent morphological changes that prevent image capture. In the absence of Q-VD-OPh, cells with diffuse cytochrome c-GFP rapidly blebbed and detached from the coverslip, indicating apoptosis had proceeded under these conditions (data not shown).
Heavy membrane fractions from the TNF-treated clones sequestered the active carboxyl terminal p15 fragment of BID, which was partially or completely released by coincubation with 100 nM ABT-737 or 100 nM PUMA␤, respectively ( Fig. 2A) . The release of p15 BID from the heavy membrane fractions paralleled the cellular activity of ABT-737 and PUMA␤ to induce MOMP and apoptosis in Fig. 1 C-E. Equal heavy membrane loading was confirmed by similar BCL-2 expression in each lane (Fig. 2 A) . The same heavy membrane fractions were also analyzed for cytochrome c release induced by ABT-737, PUMA␤ or the PUMA BH3 domain peptide (Fig. 2B) . Again, there was a correlation between expression, sequestration and release of p15 BID with cytochrome c release. Partial inhibition of the anti-apoptotic BCL-2 repertoire by ABT-737 treatment resulted in only partial cytochrome c release; complete inhibition by PUMA␤ or the PUMA BH3 domain peptide resulted in almost complete cytochrome c release (Fig. 2B) . As controls, the heavy membranes from each clone responded similarly to recombinant C8-BID, demonstrating equivalent capabilities to release cytochrome c. The requirement for more BH3 domain peptide compared to full-length protein to observe BH3-only protein function is consistent with other observations of direct activator and sensitizer BH3-only proteins (6, 7, 10) . To determine if the p15 BID was sequestered by anti-apoptotic BCL-2 proteins within the isolated heavy membrane fractions, BCL-2 and MCL-1 were separately immunoprecipitated and analyzed for associated p15 BID. Both anti-apoptotic proteins coimmunoprecipitated with p15 BID, which was not seen when PUMA␤ was present (Fig. 2C) . Similarly, ABT-737 prevented coimmunoprecipitation of BCL-2 and p15 BID, but not MCL-1 and p15 BID (Fig. 2C) . These data suggest the following scenario: (i) in cells, anti-apoptotic BCL-2 proteins on the OMM can sequester substantial direct activator BH3-only protein function to inhibit MOMP, cytochrome c release, and apoptosis; and (ii) complete inhibition of the anti-apoptotic BCL-2 repertoire by PUMA can release these direct activator proteins from the OMM to rapidly induce MOMP, cytochrome c release and apoptosis.
The ability of PUMA to derepress sequestered direct activator molecules at the OMM is similar to a cellular scenario termed, ''primed for death.'' (14) For example, CLL cells that undergo apoptosis in response to ABT-737 have been shown to harbor the direct activator, BIM, that appears to be derepressed by ABT-737 treatment (13, 14) . This primed for death derepression scenario (Fig. 3A) was recapitulated in vitro using C57BL/6 liver mitochondria loaded with different direct activators of BAX and/or BAK and then treated with PUMA␤ or the PUMA BH3 domain peptide (Fig. 3 B-D) . Active forms or peptides from three established direct activators were used: BID, BIM, and p53. Mitochondria were incubated with recombinant C8-BID (Fig. 3B , 5-25 pM), BIM BH3 domain peptide (Fig. 3C , 10-100 nM) or cytosolic p53 (Fig. 3D , 10-100 pM) at concentrations too low to induce MOMP, and then washed to remove any unbound direct activator. The treated mitochondria were then resuspended in buffer containing PUMA␤ (500 nM) or PUMA BH3 domain peptide (500 nM). In the p53 samples, 40 nM recombinant monomeric BAX was added along with the derepressor as we have not observed substantial p53-induced BAK activation (9) . PUMA␤ or the PUMA BH3 domain peptide did not cause cytochrome c release on its own, but when combined with direct activator pretreatment, each induced efficient, complete release ( Fig. 3 B-D) . Similarly, the addition of PUMA␤ or the PUMA BH3 domain peptide plus recombinant BAX did not induce MOMP unless mitochondria were previously treated with p53 (Fig. 3D) . The results support the notion that PUMA can release direct activator proteins or peptides from the OMM to induce MOMP in a manner similar to that observed with mitochondria derived from tumor cells (13, 14) . Also, PUMA did not discriminate between the direct activators; C8-BID, BIM BH3 peptide, and cytosolic p53 were equally derepressed from the anti-apoptotic BCL-2 repertoire to activate BAX and/or BAK and induce MOMP.
Complementary to the primed for death scenario above is the ''sensitized for death'' function of BH3-only proteins by which it is hypothesized that inhibition of the anti-apoptotic BCL-2 repertoire increases mitochondrial sensitivity to direct activator BH3-only proteins (Fig. 3E) . To examine this scenario, C57BL/6 mitochondria were treated with PUMA␤ (250 nM) or the PUMA BH3 domain peptide (250 nM), washed, and then treated with subMOMPinducing concentrations of C8-BID (Fig. 3F, 5-25 pM) , BIM BH3 domain peptide (Fig. 3G, 10-100 nM) or cytosolic p53 (Fig. 3H,  10 -100 pM). Pretreatment with either PUMA␤ or the PUMA BH3 domain peptide sensitized mitochondria to direct activator proteins by approximately 100-200-fold (e.g., 1 nM C8-BID is normally required for complete MOMP; 5-10 pM C8-BID were sufficient to induce MOMP from PUMA pretreated mitochondria). In contrast, an additional treatment of PUMA␤ (500 nM final) or the PUMA BH3 domain peptide (500 nM final) without direct activators did not cause cytochrome c release even though this was 50,000-fold excess compared to the 5 pM C8-BID treatment (Fig. 3 F-G , ''2X PUMA␤'' and ''2X PUMA BH3''). Therefore, in addition to a derepression function, PUMA can also regulate MOMP by sensitizing mitochondria to a normally tolerated dose of direct activator protein stimulation. These data biochemically define PUMA as a derepressor/sensitizer BH3-only protein.
Next, we used three defined derepression model systems with purified recombinant proteins to observe PUMA cooperation within a direct activator:anti-apoptotic:derepressor network in vitro. In the first, C57BL/6 (Ͻ 3 months old) liver mitochondria (which express BCL-2, BCL-xL, MCL-1, and BAK, but no detectable BH3-only proteins, data not shown) were induced to release cytochrome c with C8-BID, and this was inhibited by either recombinant BCL-xL lacking the C terminus (BCL-xL⌬C) or recombinant MCL-1⌬C (Fig. 4A) . Addition of PUMA␤ or the PUMA BH3 domain peptide inhibited the anti-apoptotic effects to reveal C8-BID activity (Fig. 4A) . As a control, the BAD BH3 domain peptide, which can bind BCL-xL but not MCL-1 (7, 21) , derepressed only the C8-BID:BCL-xL⌬C complex and not C8-BID:MCL-1⌬C to promote MOMP (Fig. 4A ). In the absence of C8-BID, no effects of PUMA␤, PUMA BH3 peptide, or BAD BH3 peptide were observed.
We also used a cellular derepression model system in which HeLa cells stably express cytochrome c-GFP. These cells do not constitutively express and sequester direct activator proteins (the parental cells to the TNF-treated clones in Fig. 1) (7) . HeLa cells microinjected with C8-BID underwent complete cytochrome c release, which was defined by the conversion of a punctate (mitochondrial) to a diffuse cytosolic (released from mitochondria) pattern of the cytochrome c-GFP (Fig. 4B) . This release was inhibited by coinjection of BCL-xL⌬C; and derepression of the C8-BID:BCL-xL⌬C complex occurred when recombinant PU-MA␤ was added (Fig. 4B) . Texas Red dextran was combined with all protein solutions to identify cells that were microinjected. Neither full-length BID (FL-BID) nor PUMA␤ alone induced a diffuse cytochrome c-GFP pattern (Fig. 4B) . The percentage of cells responding to each microinjection scenario is indicated in the representative cell image. Similar results were also observed for PUMA␤-mediated derepression of the C8-BID:MCL-1⌬C complex (data not shown).
Finally, we used a large unilamellar vesicle (LUV) model system that faithfully mimics BCL-2 family dependent and regulated BAX activation and MOMP (7, 8) caspase 8 site (22)) acted with similar kinetics and concentrations as C8-BID (data not shown). BAX plus 0.045 M N/C-BID efficiently induced the release of F-dextran, which was inhibited by either full-length BCL-xL or MCL-1 (Fig. 4C ). The addition of PUMA␤ derepressed both the N/C-BID:BCL-xL and N/C-BID:MCL-1 complexes to promote LUV permeabilization (Fig.  4C) . To ensure N/C-BID was responsible for LUV permeabilization, the ability of PUMA␤ to activate BAX was also measured. PUMA␤ at concentrations similar to maximal release induced by N/C-BID (0.01-0.1 M) failed to synergize with BAX, and higher concentrations of PUMA␤ (up to 6 M, 133-fold more than 0.045 M N/C-BID) also displayed minimal direct activator function in these assays (Fig. 4C) . The PUMA BH3 domain peptide also weakly activated of BAX in this system (7) . PUMA␤ only promoted BAX activation when a direct activator:anti-apoptotic complex was present and PUMA␤ could fully derepress BCL-xL or MCL-1-mediated inhibition of N/C-BID. These data further support the hypothesis that PUMA functions within a direct activator:anti-apoptotic:derepressor network to reveal direct activator BH3-only protein function using isolated mitochondrial (Fig. 4A) , cellular (Fig. 4B) , and LUV (Fig. 4C ) derepression model systems. The original descriptions of PUMA suggested that it was the key pro-apoptotic p53 target gene required for p53 dependent, DNAdamage induced apoptosis as exogenous over-expression of PUMA was sufficient to induce cell death in p53 deficient cells (15) (16) (17) . To determine if PUMA may function via derepression of covert direct activator BH3-only proteins in untreated, healthy, proliferating cells, we transiently transfected SV40 large T antigen expressing wild-type, bid Ϫ/Ϫ , bim Ϫ/Ϫ or bid Ϫ/Ϫ bim Ϫ/Ϫ mouse embryonic fibroblasts (MEFs) with an increasing amount (0, 10, 25, 50, and 100 ng) of PUMA␣ cDNA before assaying for apoptosis by annexin V staining and flow cytometry. Wild-type MEFs underwent a dosedependent increase in annexin V staining and loss of survival (Fig.  S3a) , whereas genetic deletion of bid or bim, but more significantly the latter, produced resistance to exogenous PUMA␣ expression. We also compared the effects of PUMA␣ and PUMA␤ transient expression in the same panel of MEFs and found the range of 50-100 ng of PUMA␣ or PUMA␤ cDNA allowed for reproducible The sensitized for death model system. In this situation, anti-apoptotic BCL-2 proteins are saturated with derepressor proteins allowing trivial direct activator stimulation to escape inhibition and MOMP is engaged. Experimentally, mitochondria are pretreated with a derepressor/sensitizer before direct activator stimulation. (F-H) Isolated C57BL/6 mitochondrial fractions were pretreated with DMSO (vehicle), PUMA␤ or PUMA BH3 domain peptide for 30 min at 37°C, then the direct activator proteins, C8-BID (F), BIM BH3 domain peptide (G) or p53 (H) were added, incubated for 60 min at 37°C and the samples were fractionated for the supernatant. Instead of adding a direct activator protein, another dose of PUMA␤ or PUMA BH3 domain peptide (500 nM final) was added to the ''2X PUMA␤'' and ''2X PUMA BH3'' samples, respectively. The entire p53 panel also contains BAX protein. Total cytochrome c was determined by a sample containing mitochondria solubilized in 1% CHAPS.
differences among the indicated MEFs (Fig. 5A, Fig. S3A ). Increasing the dose of transfected PUMA␣ or PUMA␤ cDNA ten-to twenty-fold (i.e., 1000 ng) markedly reduced the differences between the genotypes (Fig. S3B) , which likely parallels the first observations on PUMA-induced apoptosis. Western blot analysis of whole cell lysates confirmed similar exogenous expression of PUMA (Fig. S3C ) and indicated genetic deletions (Fig. 5B) in the MEF panel. For comparison, endogenous PUMA␣ expression in wild-type MEFs following UV radiation, actinomycin D and VP16 was similar to the levels achieved by approximately 50-100 ng of PUMA␣ cDNA and did not elevate to levels produced by 1000 ng of PUMA␣ cDNA (Fig. S4 A and B) . From these observations, we propose that stress-induced levels of PUMA cooperate with direct activator proteins (e.g., BID and BIM) to efficiently promote MOMP and apoptosis. Healthy cells also appear to harbor covert levels of direct activator BH3-only proteins that can be revealed by exogenous PUMA expression (Fig. 5A) .
In vitro, we examined the cooperation between PUMA and direct activator BH3-only proteins using primary murine liver heavy membrane fractions from untreated wild-type, bid Ϫ/Ϫ , bim Ϫ/Ϫ and bid Ϫ/Ϫ bim Ϫ/Ϫ animals. These heavy membrane fractions were first stimulated with C8-BID or the BID BH3 domain peptide to ensure that each can respond to direct activator stimulation (Fig. 5C ). Both C8-BID protein (0.1-1 nM) and BID BH3 domain peptide (100-500 nM) efficiently induced complete cytochrome c release from all of the genotypes (Fig. 5C) . The same concentrations of PUMA␤ or the PUMA BH3 domain peptide failed to promote cytochrome c release using standard Western blot exposure times (Fig. S5A) . Marked over-exposure of the PUMA BH3 domain peptide titration revealed minor cytochrome c release that was completely dependent on the presence of bid and bim (Fig. S5B ) and unrelated to availability of cytochrome c for release (Fig. S6A) (23) . Increasing the concentrations of PUMA␤ and the PUMA BH3 domain peptide (up to 5 and 100 M, respectively) promoted more cytochrome c release but this was also mostly dependent upon endogenous bid and bim expression (Fig. 5D) . The heavy membrane fractions from each genotype were confirmed by Western blot analysis (Fig. 5E ). These data suggest that mitochondria derived from healthy primary tissues also harbor direct activator proteins, which are functional only when the entire anti-apoptotic BCL-2 is inhibited, in this case, by PUMA treatment. The BH3-only proteins function in cooperation with the BCL-2 effector proteins, BAX and BAK, to induce MOMP and subsequent apoptosis. It is hypothesized that one or more direct activator proteins are involved in many cellular stresses leading to the mitochondrial pathway of apoptosis, as these are required to engage BAX and/or BAK activation regardless of the apoptotic stimulus. The derepressor/sensitizer BH3-only proteins appear to act as sentinels for specific cellular stress pathways and liberate direct activator function at the OMM, as genetic deletion of individual members renders cells resistant to specific stress scenarios; for example, hrk-and puma-deficient animals exhibit defects in nerve growthfactorwithdrawalandcytokinedeprivation-dependentapoptosis, respectively (15, 24) . Here, we were interested in understanding the cooperation between PUMA and preexisting direct activator proteins to engage the mitochondrial pathway of apoptosis. To explore this relationship, we used several derepression model systems where intact cells, mitochondria, or defined LUVs responded to direct activator proteins only upon inhibition of the anti-apoptotic BCL-2 repertoire by PUMA. Common to the cellular and mitochondrial derepression model systems was a direct activator:anti-apoptotic BCL-2 protein complex at the OMM (for example, C8-BID:BCL-2/BCL-xL/MCL-1 in Figs. 1 and 2 ); yet despite this association, mitochondria maintained their integrity (Figs. 1, 2 , 3, 4 and 5) and cells remained viable (Figs. 1 and 5 ). These scenarios highlight the importance and fidelity of anti-apoptotic proteins on the OMM to inhibit unwarranted MOMP and apoptosis. The actively sequestered molecules may also be one mechanism for a cell to record its recent history of stressful encounters. In the event of sustained or irreparable stress, these sequestered molecules could provide a rapid means to induce apoptosis. When PUMA expression is a response stress (or ABT-737 is present), our data suggest that the kinetics and efficiency of MOMP are greatly enhanced.
Materials and Methods
Reagents. All cell culture and transfection reagents were from Invitrogen; AnnexinV conjugates were from Caltag. Immortalized MEFS were produced by transfecting primary, unpassaged MEFs with SV40 genomic DNA and selected by colony formation and growth. pCMVneoBam-FLAG-PUMA␣/␤ were a gift from Karen Vousden (16) . HeLa cells stably expressing cytochrome c-GFP were made as described (19) . Antibodies: anti-PUMA (Cell Signaling), anti-BID (PharMingen, 550365), anti-BIM (Sigma), anti-actin (ICN, clone c4), anti-cytochrome c (for flow cytometry, clone 6H2.B4; for Western blot analysis, clone 7H8.2C12 PharMingen), anti-BAK (Upstate, clone NT), anti-BCL-2 (10C4), anti-BCL-xL (clone S-18), anti-A1 (FL-175), anti-MCL-1 (Rockland) and anti-p53 (Do7). Full-length human BID (FL-BID), C8-BID, and human BCL-xL⌬C (except for NMR studies) were from R&D Systems. Human full-length MCL-1, full-length BCL-xL, MCL-1⌬C, p53UVIP-referred to as ''cytosolic p53''-N/C-BID, and full-length BAX were made as described (7, 9, (25) (26) (27) . BH3 domain peptides: human BAD, BID, BIM, and PUMA (Ͼ98% purity, Anaspec) sequences as described (7) . All peptides were resuspended in anhydrous DMSO in a N2 environment, stored at Ϫ80°C, and thawed only once. PCR primers for the bid Ϫ/Ϫ animals were: 17B14, 5Ј-ccgaaatgtcccataagag-3Ј; JR23PGK-neo, 5Ј-tgctacttccatttgtcacgtcct-3Ј; 17B12, 5Ј-gagatggaccacaacatc-3Ј; wild-type (17B12 and 17B14) and knockout (17B12 and JR23PGK-neo) PCRs amplify a 123-and 350-base pair product, respectively. PCR primers for the bim Ϫ/Ϫ animals were: PB20, 5Ј-cattctcgtaagtccgagtct-3Ј; PB65, 5Ј-ctcagtccattcatcaacag-3Ј; PB335, 5Ј-gtgctaactgaaaccagattag-3Ј; wild-type (PB20 and PB335) and knockout (PB20 and PB65) PCRs amplify a 380-and 540-base pair product, respectively. Combined bid Ϫ/Ϫ bim Ϫ/Ϫ genomic samples were analyzed by both sets of PCR reactions. For detailed materials and methods, please refer to SI Materials.
